Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyHarvard Pilgrim acne rosacea coverage update | Ope…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    Medical Necessity Guidelines: Acne and Rosacea Medications

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization criteria for topical and related medications used to treat acne vulgaris, rosacea, and select dermatologic conditions for Harvard Pilgrim Health Care members (excludes Medicare members). Applies to pharmacy and medical benefits where specified.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyMedical Necessity Guidelines: Acne and Rosacea Medications
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateAug 11, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionObtain and document prior treatment history showing inadequate response or intolerance to required prior/topical therapies when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PA, QL, STPACoverage controls
    MultipleFDA‑approved agents listed
    Excludes MedicarePopulation exclusion
    Failure of ≥2 topicalsStep requirements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    None listedBilling codes

    Coverage Criteria

    Product-specific medical necessity criteria

    Covered when ALL of the following are met (per product-specific criteria below):

    Adapalene: The Member had an insufficient response to therapy with tretinoin
    Alitretinoin (Panretin): 1) Documented diagnosis of AIDS-related Kaposi's sarcoma AND 2) Documentation the Member does not require systemic anti-Kaposi's sarcoma therapy

    Systemic therapy considerations referenced in FDA indication text; Panretin is not indicated when systemic anti-KS therapy is required (e.g., >10 new KS lesions in prior month, symptomatic lymphedema, symptomatic pulmonary or visceral involvement).

    Azelaic Acid Foam (Finacea): 1) Documented diagnosis of rosacea AND 2) An inadequate response or intolerance to generic metronidazole gel and at least one additional generic topical agent used for the treatment of rosacea
    Azelaic Acid Cream (Azelex): 1) Documented diagnosis of acne AND 2) An inadequate response to therapy with tretinoin
    Benzoyl peroxide: The Member had an insufficient response to therapy with two of the preferred benzoyl peroxide products
    Brimonidine Gel (Mirvaso): 1) Member is at least 18 years of age with a diagnosis of persistent (nontransient) erythema of rosacea AND 2) The Member had an insufficient response to at least two alternative generic topical products (e.g., metronidazole, sulfacetamide, retinoid, clindamycin)
    Clascoterone Cream (Winlevi): 1) Diagnosis of acne vulgaris AND 2) The Member has had an inadequate response or intolerance to two or has a contraindication to all of the following: a) spironolactone; b) topical antibiotic (e.g., clindamycin, erythromycin); c) oral tetracycline (e.g., minocycline, doxycycline); d) retinoic acid derivative (e.g., tretinoin, adapalene, isotretinoin); e) benzoyl peroxide
    Clindamycin Foam: The Member has had an inadequate response to therapy with two preferred topical clindamycin formulations
    Clindamycin/Benzoyl Peroxide: 1) Insufficient response to concurrent therapy with the individual topical ingredients (clindamycin and prescription-strength benzoyl peroxide) AND 2) Request is for a generic (AB-rated) formulation
    Erythromycin/Benzoyl Peroxide: 1) Inadequate response to concurrent therapy with the individual topical ingredients (erythromycin and prescription-strength benzoyl peroxide) AND 2) Request is for a generic (AB-rated) formulation

    Clindamycin/Benzoyl Peroxide

    Covered when ALL of the following are met for clindamycin/benzoyl peroxide:

    Clindamycin/Benzoyl Peroxide: 1. The Member had an insufficient response to concurrent therapy with the individual topical ingredients, clindamycin and prescription-strength benzoyl peroxide. AND 2. The request is for a generic (AB-rated) formulation

    Erythromycin/Benzoyl Peroxide

    Covered when ALL of the following are met for erythromycin/benzoyl peroxide:

    Erythromycin/Benzoyl Peroxide: 1. The Member has had an inadequate response to concurrent therapy with the individual topical ingredients, erythromycin and prescription-strength benzoyl peroxide. AND 2. The request is for a generic (AB-rated) formulation

    Dapsone (Aczone)

    Covered when ALL of the following are met for dapsone (Aczone 5% and 7.5% gel):

    Dapsone (Aczone): 1. The Member had an insufficient response to therapy with at least two alternative topical products: benzoyl peroxide, erythromycin, clindamycin, sulfacetamide or sulfacetamide/sulfur

    Ivermectin (Soolantra)

    Covered when ALL of the following are met for ivermectin 1% cream (Soolantra):

    Ivermectin 1% cream (Soolantra): 1. The Member had an insufficient response to therapy metronidazole and at least one additional generic topical agent used for the treatment of rosacea

    Noritate (metronidazole) 1% cream

    Covered when ALL of the following are met for Noritate (metronidazole) 1% cream:

    Noritate (metronidazole) 1% cream: 1. The Member had an insufficient response to therapy with metronidazole 0.75% cream, gel or lotion AND 2. The Member had an insufficient response to therapy with generic metronidazole 1% gel

    Tazarotene

    Covered when ANY of the following are met for tazarotene:

    Tazarotene: 1. The Member had an insufficient response to therapy with tretinoin OR 2. The request is for an alternative dermatological inflammatory condition, such as plaque psoriasis

    Tretinoin

    Covered when ALL of the following are met for tretinoin:

    Tretinoin: 1. The request is for the treatment of acne, rosacea, cutaneous carcinoma, keratosis follicularis or verruca plana (flat warts) AND 2. If the request is for a non-preferred formulation or brand product: Member had an insufficient response to therapy with at least two preferred tretinoin formulations. Preferred formulations include generic tretinoin 0.025%, 0.05% and 0.1% cream, and generic tretinoin 0.01% and 0.025% gel AND 3. The Member is 12 years of age or older

    This guideline does not apply to Medicare Members (includes dual eligible Members).

    Products packaged as medicated swabs or in pump dispensers are noncovered when bulk packaging is available. In addition, these topical products will not be approved for cosmetic purposes.

    Coverage designations vary by product and formulation. Certain agents and formulations are designated as Prior Authorization (PA), some carry a Quantity Limit (QL), and others require Step Therapy (STPA) as noted in the formulary listing. Examples include Finacea foam (PA), Azelex cream (PA; QL), many clindamycin-benzoyl peroxide combination gels (PA), and several tretinoin and tazarotene formulations that are PA or STPA. Requests that do not meet the specified prior-treatment or PA/step requirements will not be authorized.

    Requests for brand-name products that have AB-rated generic equivalents will be reviewed under the plan's Brand Name criteria. Brand-name requests may be denied if the Brand Name criteria are not met.

    Coding

    Provider Actions and Administrative Requirements

    Prior Authorization

    Obtain prior authorization for many branded topical acne/rosacea products

    Many topical acne and rosacea formulations require prior authorization. Examples listed in the formulary include branded products such as Finacea (azelaic acid 15% foam), Mirvaso (brimonidine gel), Soolantra (ivermectin 1% cream), Winlevi (clascoterone 1% cream), Panretin (alitretinoin 0.1% gel), and several tazarotene and tretinoin formulations — each designated PA where indicated in the product listing.

    • Finacea 15% foam — Coverage = PA (azelaic acid products) [[see formulary]]
    • Mirvaso (brimonidine 0.33% gel) — Coverage = PA
    • Soolantra (ivermectin 1% cream) — Coverage = PA
    • Winlevi (clascoterone 1% cream) — Coverage = PA
    • Panretin (alitretinoin 0.1% gel) — Coverage = PA
    • Multiple tazarotene and tretinoin formulations listed as PA
    Prior Authorization

    Require PA when step-therapy criteria or prior-treatment failures are specified

    Background

    This guideline lists FDA‑approved topical medications used to treat acne vulgaris, rosacea, topical tazarotene for plaque psoriasis and other dermatologic indications (for example, Panretin for Kaposi's sarcoma). Coverage determinations are tied to the documented diagnosis and specified prior-therapy or age limits for each product.

    Definitions and Preferred Formulations

    PA / QL / STPA
    PAPrior Authorization
    QLQuantity Limit
    STPAStep Therapy Required
    Preferred tretinoin formulations
    Preferred tretinoin creamsGeneric tretinoin 0.025%, 0.05%, and 0.1% cream
    Preferred tretinoin gelsGeneric tretinoin 0.01% and 0.025% gel
    Use requirementMember must have had insufficient response to at least two preferred tretinoin formulations for non-preferred or brand requests
    Policy Summary
    Payerharvard pilgrim health care
    PolicyMedical Necessity Guidelines: Acne and Rosacea Medications
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateAug 11, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionObtain and document prior treatment history showing inadequate response or intolerance to required prior/topical therapies when requesting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Administrative RequirementsBackgroundDefinitions and Preferred Formulations

    Prior authorization is required when the product’s criteria include step-therapy or prior treatment requirements. Requests must document that the member has failed or been intolerant to the specified prior therapies (and meet any age limits) before PA will be approved.

    • Clindamycin/benzoyl peroxide and erythromycin/benzoyl peroxide require documented insufficient response to concurrent therapy with the individual components.
    • Dapsone, ivermectin, tazarotene, and non-preferred tretinoin formulations require documented prior trials as specified in product criteria.
    • Age-based PA rules apply for tretinoin (Members ≥26 years may have PA for preferred agents).
    Step Therapy

    Follow step-therapy for specified vitamin A derivatives and tazarotene/tretinoin

    Step therapy (STPA) is required for select vitamin A derivatives and tazarotene/tretinoin products as noted in the formulary; adapalene and tazarotene entries are marked STPA where indicated.

    • Adapalene 0.1% (cream, gel, lotion) — Coverage = STPA*
    • Tazarotene 0.05/0.1% (cream, gel) — Coverage = STPA*
    • Tretinoin formulations have age- and formulation-specific STPA/PA designations per the listing
    Step Therapy

    Document specific step-therapy failures for listed agents

    Step therapy applies across multiple agents and must be documented per the product criteria. For combination products, failure of individual components is required before the combination will be covered.

    • Clindamycin/benzoyl peroxide — insufficient response to concurrent therapy with clindamycin and prescription-strength benzoyl peroxide required.
    • Erythromycin/benzoyl peroxide — inadequate response to concurrent erythromycin and prescription-strength benzoyl peroxide required.
    • Dapsone (Aczone) — failure of at least two alternative topicals (benzoyl peroxide, erythromycin, clindamycin, sulfacetamide, sulfacetamide/sulfur).
    • Ivermectin (Soolantra) — insufficient response to metronidazole plus one additional generic topical for rosacea.
    • Non-preferred or brand tretinoin — trial of two preferred tretinoin formulations required.
    Documentation Required

    Document diagnosis and prior treatment history per product criteria

    Providers must document the member’s diagnosis and prior treatment history exactly as required by the product-specific criteria (including age where specified) to support a PA or step-therapy exception.

    • Include documented diagnosis (e.g., rosacea, acne vulgaris, Kaposi's sarcoma) per the product criteria.
    • Detail prior therapies tried, durations, and reasons for inadequate response or intolerance.
    Documentation Required

    Support PA with prior-therapy details that match the criteria

    When step or PA criteria require prior therapy, documentation must specifically show inadequate response to the named alternatives — for example, two preferred tretinoin formulations for non-preferred or brand tretinoin, or metronidazole plus one additional topical for ivermectin.

    • Non-preferred or brand tretinoin — member had insufficient response to at least two preferred tretinoin formulations (generic tretinoin 0.025%, 0.05%, 0.1% cream; generic tretinoin 0.01%, 0.025% gel).
    • Dapsone — insufficient response to at least two alternative topical products (listed).
    • Ivermectin (Soolantra) — insufficient response to metronidazole and at least one additional generic topical.
    Denial Risk

    Denial risk if all required criteria are not met

    Requests may be denied if the member does not meet all stated criteria — all conditions listed in a product’s criteria must be satisfied for authorization to be granted.

    • Authorization requires that ALL listed criteria for the product are met; missing required prior trials, age limits, or diagnosis documentation are grounds for denial.
    Billing Rule

    Noncoverage for swabs/pump packaging and Brand Name review for AB-rated generics

    Products packaged as medicated swabs or in pump dispensers are noncovered when bulk packaging is available; requests for brand-name products with AB-rated generics will be reviewed under Brand Name criteria and may be denied if Brand Name criteria are not met.

    • Medicated swabs or pump-dispensed products are noncovered when equivalent bulk packaging exists.
    • Brand-name products with AB-rated generics are subject to Brand Name review and may be denied if criteria are not satisfied.